The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of Action
Lung Cancer, Brain Tumor, Liver Cancer
About this trial
This is an interventional treatment trial for Lung Cancer focused on measuring Propofol, Sevoflurane, Survival
Eligibility Criteria
Inclusion Criteria: eighteen to eighty-year-old ASA class I-III patients Elective surgery for brain, liver, lungs, ovarian cancer under general anesthesia Exclusion Criteria: Severe mental disorder, poor liver function, pregnant or lactating women, morbidly obese, allergy to any of the drugs used in this study, recurrent tumor or repeat surgery, biopsy cases, incomplete outcome-data, palliative treatment after surgery, simultaneous treatment of other malignancies, emergency surgery, presence of other malignant tumors, combined propofol and inhalation anesthesia or other anesthetics, such as ketamine or dexmedetomidine, diagnosed as benign brain, liver, lungs, ovarian cancer、cell carcinoma or other metastatic.
Sites / Locations
- Kaohsiung Medical University Chung-Ho Memorial HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Sevoflurane
Propofol
The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.